Tiziana Life Sciences (Tiziana Life Sciences) Cash-to-Debt : 18.69 (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Tiziana Life Sciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Tiziana Life Sciences's cash to debt ratio for the quarter that ended in Jun. 2023 was 18.69.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Tiziana Life Sciences could pay off its debt using the cash in hand for the quarter that ended in Jun. 2023.

The historical rank and industry rank for Tiziana Life Sciences's Cash-to-Debt or its related term are showing as below:

TLSA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.1 Med: 37.6 Max: No Debt
Current: 18.69

During the past 13 years, Tiziana Life Sciences's highest Cash to Debt Ratio was No Debt. The lowest was 0.10. And the median was 37.60.

TLSA's Cash-to-Debt is ranked better than
64.11% of 1541 companies
in the Biotechnology industry
Industry Median: 6.49 vs TLSA: 18.69

Tiziana Life Sciences Cash-to-Debt Historical Data

The historical data trend for Tiziana Life Sciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Tiziana Life Sciences Cash-to-Debt Chart

Tiziana Life Sciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

0.25

118.60

No Debt

49.65

Tiziana Life Sciences Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Cash-to-Debt	Get a 7-Day Free Trial															46.46	No Debt	No Debt	49.65	18.69

Competitive Comparison of Tiziana Life Sciences's Cash-to-Debt

For the Biotechnology subindustry, Tiziana Life Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tiziana Life Sciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tiziana Life Sciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Tiziana Life Sciences's Cash-to-Debt falls into.

Tiziana Life Sciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Tiziana Life Sciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	18.122	/	(0.122	+	0.243)
	=	49.65

Tiziana Life Sciences's Cash to Debt Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	6.597	/	(0.17	+	0.183)
	=	18.69

Tiziana Life Sciences (NAS:TLSA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Tiziana Life Sciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Tiziana Life Sciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Tiziana Life Sciences (Tiziana Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tiziana Life Sciences Ltd (NAS:TLSA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

0RP:Germany

Address

2 Church Street, Clarendon House, Hamilton, BMU, HM 11

Website

https://www.tizianalifesciences.com

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experience.